Medicare AdvantagePrior AuthMedium impact
Qudexy XR®, Trokendi XR® (topiramate) (New)
Humana·Neurology, Family Medicine, Internal Medicine +1 more·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Qudexy XR and Trokendi XR (topiramate extended-release) effective January 1, 2026. Requires specific age criteria, diagnosis documentation, and proof of previous treatment failures or contraindications for migraine prevention and epilepsy treatment.
Action Required
By January 1, 2026: Billing team must implement prior authorization requirements for Qudexy XR and Trokendi XR prescriptions. Update system to verify age requirements (12+ for migraine, 2+ for Qudexy XR epilepsy, 6+ for Trokendi XR epilepsy), document previous treatment failures with immediate-release topiramate, and for migraine cases, confirm trial/contraindication of antidepressants. Providers must complete prior auth forms before prescribing or claims will be denied.